A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity-Reference-Cited by-同舟云学术

A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity

Published:2020-12-07 Issue:3 Volume:178 Page:600-613
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:Br J Pharmacol

Author:

Jones Rhys D.O.¹^ORCID,Grondine Mike²,Borodovsky Alexandra³,San Martin Maryann²,DuPont Michelle²,D'Cruz Celina²,Schuller Alwin²,Henry Ryan³,Barry Evan³,Castriotta Lillian²,Anjum Rana²,Petersson Klas⁴,Sahota Tarjinder⁵,Ahmed Ghada F.⁶

Affiliation:

1. Oncology R&D, Research and Early Development AstraZeneca Cambridge UK

2. Oncology R&D, Research and Early Development AstraZeneca Boston Massachusetts USA

3. Formerly Oncology R&D, Research and Early Development AstraZeneca Boston Massachusetts USA

4. qPharmetra LLC Stockholm Sweden

5. BioPharmaceuticals R&D, Clinical Pharmacology and Safety Sciences AstraZeneca Cambridge UK

6. Formerly BioPharmaceuticals R&D, Clinical Pharmacology and Safety Sciences AstraZeneca Cambridge UK

Funder

AstraZeneca

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.15301

Reference42 articles.

1. Ahn M.‐J. Cantarini M. Frewer P. Hawkins G. Peters J. A. Howarth P. …Oxnard G.(2019).SAVANNAH: Phase II trial of osimertinib plus savolitinib in EGFR‐mutant MET‐driven advanced NSCLC following prior osimertinib (Poster P1.01‐134). Paper presented at the IASLC 2019 World Conference on Lung Cancer (WCLC) Barcelona Spain 7–10 September 2019.

2. MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array

3. The Concise Guide to PHARMACOLOGY 2019/20: Catalytic receptors;Alexander S. P. H.;British Journal of Pharmacology,2019

4. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

5. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combination of osimertinib and savolitinib as molecular inhibition of EGFR and MET receptors may be selected to provide maximum effectiveness and acceptable toxicity;Translational Lung Cancer Research;2024-06

2. Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper;Clinical Pharmacology & Therapeutics;2024-05-16

3. Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model;Molecular Cancer Therapeutics;2023-03-08

4. Savolitinib for non-small cell lung cancer;Drugs of Today;2023-01

5. Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review;Cancers;2022-12-12